MedMira Engages Distributor for Middle East

MedMira Engages Distributor for Middle East
Rapid HIV Test to be Carried by Established Distributor 


HALIFAX, Dec. 7  /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through
diagnostic technology, announced today that it has engaged the Prestige Group
of Abu Dhabi, the medical device and pharmaceuticals division of the US $4.5
billion Al Jaber Group of Establishments, to distribute its MiraWell(TM) Rapid
HIV Test to the hospital and healthcare market in selected Middle East
countries. The Prestige Group is a well-established distributor in the region
with a skilled sales force, strong market presence and experience at bringing
foreign products through the regulatory process for medical devices.

The MiraWell(TM) Rapid HIV Test, in its serum, plasma and whole blood version,
is currently within the regulatory approval process for several Middle East
countries. As the fastest rapid HIV test available to the global healthcare
market, at only 3-minutes, this versatile test will provide front-line testing
capabilities and facilitate critical patient counseling to help combat the
transmission of HIV throughout the region.

Giles Crouch, vice president marketing and business development of MedMira
said, "Prestige Group, the latest addition to our continually expanding
distribution network, is an excellent example of our commitment to find and
engage qualified, well-established companies with country-specific experience
to market our products." Crouch continued, "We anticipate steady market growth
in the Middle East as rapid HIV testing is incorporated as a primary
application in local healthcare systems." Initial orders for MedMira's rapid
HIV tests are expected within the next couple of months, upon completion of the
regulatory approval process.

The WHO estimates that approximately 83,000 people were newly infected with HIV
in this region in 2003 and that about 0.3 percent of adults are currently
infected. Recent evidence suggests that the HIV infection rate is increasing,
and that the total number of AIDS deaths has increased almost six-fold since
the early 1990's.

About MedMira

MedMira is the leading global manufacturer and marketer of in vitro flow-though
rapid diagnostic tests for the clinical laboratory market. MedMira's tests
provide reliable, rapid diagnosis in just 3 minutes for the detection of human
antibodies in human serum, plasma or whole blood for diseases such as HIV. The
United States FDA and the SFDA in the People's Republic of China have approved
MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For
more information visit MedMira's website at http://www.medmira.com/.

This news release contains forward-looking statements, which involve risk and
uncertainties and reflect the company's current expectation regarding future
events. Actual events could materially differ from those projected herein and
depend on a number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of corporate
alliances and other risks detailed from time to time in the company quarterly
filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this statement. 

DATASOURCE: MedMira Inc.



CONTACT: Media Contact: Investor Relations: Dr. James Smith:

[phone] or e-mail: 

Copyright